IL289657A - Pharmaceutical formulations containing gaboxadol for medical treatment - Google Patents
Pharmaceutical formulations containing gaboxadol for medical treatmentInfo
- Publication number
- IL289657A IL289657A IL289657A IL28965722A IL289657A IL 289657 A IL289657 A IL 289657A IL 289657 A IL289657 A IL 289657A IL 28965722 A IL28965722 A IL 28965722A IL 289657 A IL289657 A IL 289657A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical formulations
- therapeutic treatment
- formulations containing
- containing gaboxadol
- gaboxadol
- Prior art date
Links
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title 1
- 229950004346 gaboxadol Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874152P | 2019-07-15 | 2019-07-15 | |
| PCT/US2020/042044 WO2021011597A1 (en) | 2019-07-15 | 2020-07-15 | Pharmaceutical formulations containing gaboxadol for therapeutic treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL289657A true IL289657A (en) | 2022-03-01 |
Family
ID=74211193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289657A IL289657A (en) | 2019-07-15 | 2022-01-06 | Pharmaceutical formulations containing gaboxadol for medical treatment |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20210015760A1 (enExample) |
| EP (1) | EP3982937A4 (enExample) |
| JP (1) | JP2022540917A (enExample) |
| KR (1) | KR20220035195A (enExample) |
| CN (2) | CN118141810A (enExample) |
| AU (1) | AU2020313930A1 (enExample) |
| CA (1) | CA3146737A1 (enExample) |
| IL (1) | IL289657A (enExample) |
| MX (1) | MX2022000663A (enExample) |
| WO (1) | WO2021011597A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3795156A1 (en) * | 2014-06-06 | 2021-03-24 | Ovid Therapeutics, Inc. | Pharmaceutical composition for treating angelman syndrome |
| EP3154979B1 (en) * | 2014-06-12 | 2018-03-07 | Pfizer Limited | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
| CN108024997A (zh) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
| US20170348232A1 (en) * | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| KR20230050474A (ko) * | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| EP3528807A4 (en) * | 2016-11-22 | 2020-06-17 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN |
-
2020
- 2020-07-15 EP EP20840941.7A patent/EP3982937A4/en active Pending
- 2020-07-15 WO PCT/US2020/042044 patent/WO2021011597A1/en not_active Ceased
- 2020-07-15 MX MX2022000663A patent/MX2022000663A/es unknown
- 2020-07-15 AU AU2020313930A patent/AU2020313930A1/en not_active Abandoned
- 2020-07-15 US US16/929,345 patent/US20210015760A1/en not_active Abandoned
- 2020-07-15 CN CN202410172907.XA patent/CN118141810A/zh active Pending
- 2020-07-15 JP JP2022502537A patent/JP2022540917A/ja active Pending
- 2020-07-15 KR KR1020227005115A patent/KR20220035195A/ko not_active Ceased
- 2020-07-15 CN CN202080051393.2A patent/CN114173765A/zh active Pending
- 2020-07-15 CA CA3146737A patent/CA3146737A1/en active Pending
-
2021
- 2021-10-21 US US17/507,369 patent/US20220040120A1/en not_active Abandoned
-
2022
- 2022-01-06 IL IL289657A patent/IL289657A/en unknown
-
2024
- 2024-04-09 US US18/630,105 patent/US20240252447A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210015760A1 (en) | 2021-01-21 |
| EP3982937A1 (en) | 2022-04-20 |
| KR20220035195A (ko) | 2022-03-21 |
| CN118141810A (zh) | 2024-06-07 |
| CA3146737A1 (en) | 2021-01-21 |
| AU2020313930A1 (en) | 2022-02-03 |
| MX2022000663A (es) | 2022-02-16 |
| US20240252447A1 (en) | 2024-08-01 |
| EP3982937A4 (en) | 2022-08-10 |
| US20220040120A1 (en) | 2022-02-10 |
| JP2022540917A (ja) | 2022-09-20 |
| CN114173765A (zh) | 2022-03-11 |
| WO2021011597A1 (en) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2595776B (en) | Therapeutic solid dosage forms | |
| EP3954395A4 (en) | Pharmaceutical composition for muscle disease treatment | |
| ZA202110597B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB202005852D0 (en) | Therapeutic compounds | |
| SI3870578T1 (sl) | Terapevtske spojine | |
| GB202103640D0 (en) | Therapeutic compounds | |
| GB202005863D0 (en) | Therapeutic compounds | |
| PL3743043T3 (pl) | Kompozycje farmaceutyczne do leczenia bólu pooperacyjnego | |
| IL285751A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| EP3338771A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF TRAMADOL-ETORICOXIB CHLORHYDRATE FOR THE TREATMENT OF PAIN | |
| EP3982937A4 (en) | PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT | |
| HK40073269A (en) | Pharmaceutical formulations containing gaboxadol for therapeutic treatment | |
| GB202103642D0 (en) | Therapeutic compounds | |
| GB202101161D0 (en) | Formulations for the treatment of tendinopathies | |
| ZA202201080B (en) | Improved medical apparatus for containing haematomas | |
| IL287529B (en) | A pharmaceutical combination that includes trazodone for the treatment of neuropathic pain | |
| GB202001137D0 (en) | Formulations for the treatment of tendinopathies | |
| GB202117634D0 (en) | Therapeutic apparatus | |
| HK40067363A (en) | Combination drug treatment for human cytomegalovirus | |
| GB202110728D0 (en) | Therapeutic compounds | |
| GB202101577D0 (en) | Therapeutic compounds | |
| GB202101574D0 (en) | Therapeutic compounds |